Repositioning Candidate Details
| Candidate ID: | R0736 |
| Source ID: | DB05204 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | XL418 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | XL418 is a novel anticancer compound. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Cancer |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | XL418 is a small molecule that inhibits the activity of protein kinase B (PKB or AKT) and S6 Kinase (S6K), which act downstream of phosphoinosotide-3 kinase (PI3K). Activation of these kinases is a frequent event in human tumors, promoting cell growth, survival, and resistance to chemotherapy and radiotherapy. Inactivation of the pathway through inhibition of AKT is expected to induce apoptosis (programmed cell death) in tumor cells. AKT inhibitors may also sensitize tumor cells to a wide range of chemotherapy. |
| Targets: | Tyrosine-protein kinase BTK |
| Inclusion Criteria: | Therapeutic strategy associated |
